Thyrocare Technologies (NSE:THYROCARE) EBIT: ₹2,166 Mil (TTM As of Mar. 2026)


NSE:THYROCARE Thyrocare Technologies Ltd NSE:THYROCARE
87 GF Score
Price ₹524.40
GF Value ₹391.69
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies EBIT?

Thyrocare Technologies NSE:THYROCARE +1.39% 87 EBIT is ₹2,166 Mil as of Mar. 2026. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹391.69 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Thyrocare Technologies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹660 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,166 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Thyrocare Technologies's annualized ROC % for the quarter that ended in Mar. 2026 was 41.46%. Thyrocare Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 108.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Thyrocare Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.65%.

Thyrocare Technologies  (NSE:THYROCARE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Thyrocare Technologies's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2442.4 * ( 1 - 24.41% )/( (0 + 4453.3)/ 1 )
=1846.21016/4453.3
=41.46 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7472.2 - 707.6 - ( 2311.3 - max(0, 1099.1 - 3722.9+2311.3))
=4453.3

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Thyrocare Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2638/( ( (0 + max(0, 0)) + (2086.8 + max(346.3, 0)) )/ 1 )
=2638/( ( 0 + 2433.1 )/ 1 )
=2638/2433.1
=108.42 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(738.8 + 484.6 + 106.9) - (707.6 + 0 + 276.4)
=346.3

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Thyrocare Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=2165.8/81665.191
=2.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies EBIT Related Terms

Thyrocare Technologies EBIT Historical Data

* Premium members only.

The historical data trend for Thyrocare Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies EBIT Chart

Thyrocare Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,300.90 909.40 1,001.80 1,484.90 2,156.80

Thyrocare Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 478.90 512.60 631.70 362.00 659.50

NSE:THYROCARE vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Thyrocare Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thyrocare Technologies EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Thyrocare Technologies's EV-to-EBIT falls into.


NSE:THYROCARE
87GF Score
Thyrocare Technologies Ltd NSE:THYROCARE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thyrocare Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,166 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹2,166 Mil mean?
Thyrocare Technologies (NSE:THYROCARE) has a EBIT of ₹2,166 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Thyrocare Technologies.
Is Thyrocare Technologies' EBIT too high?
Thyrocare Technologies' current EBIT is ₹2,166 Mil. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' EBIT compare to TMO and DHR?
Thyrocare Technologies' EBIT of ₹2,166 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Thyrocare Technologies. Thyrocare Technologies's current EBIT is ₹2,166 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹391.69, compared to a current price of ₹524.40 — trading 33.9% above its estimated fair value. The current EBIT is ₹2,166 Mil. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current EBIT is ₹2,166 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹524.40 is trading 33.9% above its estimated GF Value™ of ₹391.69. GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.

Key valuation signals for NSE:THYROCARE:

  • EBIT: ₹2,166 Mil
  • GF Value™: ₹391.69 vs. price of ₹524.40 (33.9% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Thyrocare Technologies Business Description

Other Exchanges 539871:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score

Get the complete analysis for NSE:THYROCARE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹524.40
Price
₹391.69
GF Value